Esperion Therapeutics (ESPR) Profit After Tax (2012 - 2026)

Esperion Therapeutics has reported Profit After Tax for 15 years, with the latest figure at -$25.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 37.72% year-over-year to -$25.2 million; the trailing twelve-month figure through Mar 2026 stood at -$7.4 million (up 95.16% YoY), and the FY2025 full-year result was -$22.7 million, up 56.17% from the prior year.
• Profit After Tax for Q1 2026 stood at -$25.2 million, down from $61.8 million in the prior quarter.
• The five-year high for Profit After Tax was $61.8 million in Q4 2025, with the low at -$66.3 million in Q2 2022.
• Historically, Profit After Tax has averaged -$31.9 million across 5 years, with a median of -$41.2 million in 2023.
• The largest YoY upside for Profit After Tax was 390.04% in 2025 against a maximum downside of 166.3% in 2025.
• Esperion Therapeutics' Profit After Tax stood at -$55.5 million in 2022, then dropped by 1.54% to -$56.3 million in 2023, then surged by 62.16% to -$21.3 million in 2024, then surged by 390.04% to $61.8 million in 2025, then tumbled by 140.75% to -$25.2 million in 2026.
• The last three Profit After Tax figures came in at -$25.2 million (Q1 2026), $61.8 million (Q4 2025), and -$31.3 million (Q3 2025), per Business Quant data.